Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).

This is because the technology is an option alongside current standard treatment options and the population is small.

This technology can only be prescribed if alemtuzumab is contraindicated or otherwise unsuitable.

There is some uncertainty around the number of people for whom alemtuzumab is contraindicated or otherwise unsuitable, for whom ocrelizumab is an option. It is estimated that between 20,000 and 25,000 may be eligible for treatment with ocrelizumab and around 10% may receive treatment.

The list price of ocrelizumab has a discount that is commercial in confidence. For enquiries about the patient access scheme contact:

The technology is commissioned by NHS England. Providers are NHS hospital trusts.

This page was last updated: 25 July 2018